What Does the Future Hold for DLBCL Care? What Direction Should New Research Take?

To conclude their discussion on diffuse large B-cell lymphoma (DLBCL), Tara Graff, DO, MS, from Mission Cancer and Blood, Ruemu Birhiray, MD, of Hematology Oncology of Indiana, Suzanne Fanning, DO, from Prisma Health Cancer Institute, and Joshua Brody, MD, of the Tisch Cancer Institute at Mount Sinai provide their outlook on the future of DLBCL care. They describe what clinical research will most help inform decision-making, current work underway they find exciting, and the progress they expect for DLBCL outcomes.